Glyxambi combines empagliflozin, a sodium glucose cotransporter-2 inhibitor that blocks the absorption of excess glucose by the kidneys so it is released through urine, and linagliptin, a DPP-4 inhibitor that increases the production of insulin by the beta cells of the pancreas while reducing the amount of glucose produced by the liver.

Read more